Three biologics targeting interleukin 5 (IL-5) or its receptor (IL-5Rα) are approved for use in patients with severe asthma. In a meta-analysis, Greek scientists have now investigated the clinical response to anti-IL-5/-5Rα biologics in real-world studies and provided insights into the use of these drugs in clinical practice.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Acute lymphoblastic leukemia
Addition of blinatumomab to chemotherapy improves survival in children
- Advanced breast cancer
Next-generation SERD therapy with promising results
- Urticaria & urticaria-like exanthema
Case studies from pediatric dermatology
- Vitiligo in children and adolescents
Just don’t bury your head in the sand!
- Psoriasis treatment with biologics
What are the latest trends?
- Innovative care concepts: HÄPPI project
Future-oriented model for interprofessional primary care
- Moderate to severe chronic hand eczema
Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland
- Study on tinnitus in everyday practice